Prof. Jeffrey V. Lazarus
Jeffrey V. Lazarus (PhD, MIH, MA) is a Professor of Global Health at the City University of New York Graduate School of Public Health and Policy. He also holds positions as a research professor at the Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, where he leads the health systems research team, and as an affiliated professor at the University of Copenhagen WHO collaborating centre on patient perspectives on medicine.
His decade-long career as health systems, HIV, and viral hepatitis expert at WHO Europe was followed by three years (2009-2012) as a senior specialist at the Global Fund to Fight AIDS, Tuberculosis, and Malaria, three years as director of Health Systems Global (2012-15) then board chair of the foundation AFEW International (2015-18).
Prof Lazarus is the chair of the Healthy Livers, Health Lives coalition, formed by AASLD, ALEH, APASL. EASL and SOLDA and he is on the leadership committee of the Global NASH Council. He is the Principal Investigator (PI) of 10 active projects and trials and is the author of more than 400 publications.
His work includes leading the NAFLD public health consensus statement (Nature Reviews GastroHep 2021), the new fatty liver disease nomenclature, published in 3 society journals (2023), the global research (J Hepatology 2023) and action priorities (Hepatology 2023), the expert recommendation on NAFLD models of care (Nature Reviews GastroHep 2021), the fatty liver disease-Sustainable Development Goals score (Hepatology 2023), and the Global COVID-19 Consensus Statement (Nature 2022), and he is a co-author of the EASL NAFLD patient guideline (JHEP Reports 2021) and the Lancet GastroHep Commission on Viral Hepatitis (2024).
He is on the editorial board of the Journal of Hepatology and Liver International. In 2023, he co-chaired the EASL SLD Summit and the Liver Connect NAFLD Summit. In 2017, he was a recipient of The Economist Intelligence Unit Change Maker award, given in recognition of significant contributions to the global elimination of hepatitis C, and in 2023 the American Liver Foundation Distinguished Scientific Achievement award.
